——, CRISP, A. H. & CALLENDER, J. (1992) Psychiatric diagnoses in recovered and non-recovered anorectics 22 years after onset of illness – pilot study. *Comprehensive Psychiatry*, **33**, 123–127.

L. K. GEORGE HSU

Eating Disorders Clinic
University of Pittsburgh
3811 O'Hara Street
Pittsburgh, PA 15213–2593

Psychiatric symptoms in cannabis users

SIR: Thomas (*Journal*, August 1993, **163**, 141–149) reviewed the evidence for 'cannabis psychosis' being valid as a diagnostic entity. We have investigated this issue empirically in a consecutive series of psychotic admissions which has been described elsewhere (Jones *et al*, *Journal*, January 1993, **162**, 65–71). The Present State Examination (PSE) was used to assess the psychopathology of 23 acute psychotic admissions who were cannabis positive on urinary screening, and 46 matched drug-free psychotic controls. Cases and controls were indistinguishable in terms of the prevalence of PSE syndromes. Moreover, the groups were also similar with respect to DSM–III–R diagnoses, ethnicity and socio-economic class, differing only, as expected, in terms of their histories of substance use.

We also examined the morbid risk of psychiatric illness in first-degree relatives, using maternal interviews and RDC–FH criteria, and Weinberg's shorter method of age correction. Cannabis positive cases had a significantly higher familial morbid risk of schizophrenia than the controls (7.1% v. 0.7%; odds ratio = 10.2; 95% CI 1.12–234, $P = 0.02$), but similar rates for other conditions.

We agree with the author's conclusion that there is little evidence to support the concept of a 'cannabis psychosis'. Furthermore, we propose that psychosis occurring in the context of cannabis use may be particularly likely in those with a genetic predisposition to psychotic illness; cannabis use may trigger a 'functional' psychosis in those with a psychotic diathesis, rather than producing a specific 'cannabis psychosis' *de novo*.

PHILIP MCGUIRE
PETER JONES
ROBIN MURRAY

Institute of Psychiatry
De Crespigny Park
Denmark Hill
London SE5 8AF

Fluoxetine – induced mania in a patient with post-stroke depression

SIR: Although mania or hypomania are well recognised side-effects of fluoxetine in depressed patients with 'functional' unipolar depression (Settle & Settle, 1984) or bipolar disorder (Lebegue, 1987), cases of mania induced by fluoxetine in patients with 'organic' mood disorders have not been reported. The following case report describes a patient with post-stroke depression (PSD), who developed mania three weeks after starting low doses of fluoxetine.

Case report. A 63-year-old right-handed woman suffered a sudden left hemiparesis and dysarthria in association with an ischemic infarction that involved the right corona radiata. Two months after the stroke, the patient became moderately depressed. Clinical features of depression included sadness, anhedonia, social withdrawal, inappropriate guilt, recurrent thoughts of death, and initial insomnia. On the 17-item Hamilton Depression Rating Scale her score was 16 points. She had no personal or family history of bipolar disorder, mania or any other psychiatric disorder.

The patient was started on a regimen of fluoxetine (20 mg/day), and over the following days her depressive symptoms became less severe. Three weeks after starting fluoxetine, she became euphoric and markedly intrusive and had pressured speech, as well as flight of ideas and increased activity and libido. She also exhibited inflated self-esteem, impulsive spending, and diminished need for sleep. She met DSM–III–R criteria for organic affective disorder, manic type, and on the Beck Mania Scale her score was 19 points (definite mania). Fluoxetine was discontinued. Lithium carbonate (800 mg/day) was started, and the patient experienced a rapid recovery.

Nortriptyline, trazodone and electroconvulsive therapy have all been reported to be effective and safe for treating PSD without the induction of mania (Robinson & Starkstein, 1990). Less is known about the efficacy and side-effects of fluoxetine and other selective serotonin-reuptake inhibitors in the treatment of organic mood disorders, although Morris (1991) has recently reported recurrent orgasmic sexual experiences induced by fluoxetine in a patient with PSD.

Since post-stroke bipolar affective disorder has mainly been reported after subcortical right-hemisphere lesions (Starkstein *et al*, 1991), it is possible that in our case fluoxetine may have precipitated a latent bipolar disorder. Therefore, further studies are needed to provide information on fluoxetine's safety profile in patients with PSD and right-hemisphere damage.

LEBEGUE, B. (1987) Mania precipitated by fluoxetine (letter). *American Journal of Psychiatry*, **144**, 1620.

MORRIS, P. L. (1991) Fluoxetine and orgasmic sexual experiences. *International Journal of Psychiatry in Medicine*, **21**, 379–382.

ROBINSON, R. G. & STARKSTEIN, S. E. (1990) Current research in affective disorders following stroke. *The Journal of Neuropsychiatry and Clinical Neurosciences*, **2**, 1–14.

SETTLE, E. C. JR & SETTLE, G. P. (1984) A case of mania associated with fluoxetine. *American Journal of Psychiatry*, **141**, 280–281.